CM
ITCI

Castleark Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Castleark Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,010
Closed -$4.18M – 354
2024
Q4 		$4.18M Sell
50,010
-1,870
-4% -$154K 0.15% 152
2024
Q3 		$3.8M Sell
51,880
-1,900
-4% -$143K 0.15% 140
2024
Q2 		$3.68M Sell
53,780
-450
-0.8% -$31.2K 0.15% 142
2024
Q1 		$3.75M Sell
54,230
-19,570
-27% -$1.35M 0.16% 145
2023
Q4 		$5.29M Sell
73,800
-100
-0.1% -$5.75K 0.23% 104
2023
Q3 		$3.85M Sell
73,900
-3,390
-4% -$197K 0.2% 126
2023
Q2 		$4.89M Buy
77,290
+53,120
+220% +$3.31M 0.22% 108
2023
Q1 		$1.31M Sell
24,170
-37,200
-61% -$1.8M 0.06% 179
2022
Q4 		$3.25M Sell
61,370
-26,810
-30% -$1.34M 0.17% 133
2022
Q3 		$4.1M Sell
88,180
-2,000
-2% -$104K 0.23% 114
2022
Q2 		$5.15M Buy
90,180
+49,910
+124% +$2.83M 0.28% 94
2022
Q1 		$2.46M Buy
+40,270
New +$2.09M 0.11% 171

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Castleark Management's ITCI Position: Q1 2025 in Review

Castleark Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 50,010 shares — an estimated $4.18M sold.

Castleark Management first reported a position in ITCI in Q1 2022 and held it in 12 quarters. The position peaked at $5.29M in Q4 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Castleark Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Castleark Management sold 50,010 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $4.18M.
  • Castleark Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 12 quarters.
  • Castleark Management's Intra-Cellular Therapies Inc. position peaked at $5.29M in Q4 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Castleark Management's 13F filing for Q1 2025, filed 15 May 2025.